2.38
0.27 (12.80%)
Previous Close | 2.11 |
Open | 2.14 |
Volume | 627,919 |
Avg. Volume (3M) | 241,125 |
Market Cap | 63,129,740 |
Price / Sales | 255.50 |
Price / Book | 10.10 |
52 Weeks Range | |
Earnings Date | 24 Mar 2025 - 28 Mar 2025 |
Diluted EPS (TTM) | -0.830 |
Total Debt/Equity (MRQ) | 10.50% |
Current Ratio (MRQ) | 2.22 |
Operating Cash Flow (TTM) | -19.11 M |
Levered Free Cash Flow (TTM) | -10.84 M |
Return on Assets (TTM) | -97.10% |
Return on Equity (TTM) | -290.21% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bearish | Bearish |
Biotechnology (Global) | Bearish | Bearish | |
Stock | Gain Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
Analyst Consensus | 1.5 |
Insider Activity | NA |
Price Volatility | -4.5 |
Technical Moving Averages | 0.0 |
Technical Oscillators | 2.0 |
Average | -0.25 |
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
% Held by Insiders | 4.42% |
% Held by Institutions | 9.53% |
52 Weeks Range | ||
Median | 8.00 (236.13%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 03 Jul 2025 | 8.00 (236.13%) | Buy | 1.97 |
19 May 2025 | 8.00 (236.13%) | Buy | 1.96 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |